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In this issue of Immunity, Mrass et al. (2008) report that CD44 critically contributes to the stabilization of
polarity inmigrating cytotoxic T lymphocytes by anchoring cytoskeletal proteins to the cell membrane at their
uropods.Since the identification of CD44 as the
principal receptor for the extracellular
matrix (ECM) molecule hyaluronan (HA)
almost 20 years ago (Aruffo et al., 1990),
this protein has puzzled immunologists
by virtue of its manifold, at times seem-
ingly contradictory roles. Widely ex-
pressed on almost all cells of the body, it
serves a broad set of important but
frequently redundant functions in organ
development, tissue repair, hematopoi-
esis, and immune defense. Part of the
vexing complexity of its biology probably
stems from the fact that extensive alterna-
tive splicing of the original transcript and
diverse posttranslational modifications of
the various gene products lead to the
generation of many molecular isoforms
with varying functions that are differen-
tially expressed in different cell types
and at different developmental stages of
the same cell type (Ponta et al., 2003).
Naive T cells, like most cells of the
immune system in their resting states,
express the shortest CD44 splice variant
(called CD44s or CD44h), which does
not confer binding to HA. It is only upon
activation and induction of effector differ-entiation that T cells express the CD44v5
isoform and that a fraction of them tran-
siently acquire the capability to bind HA
via CD44 (Lesley et al., 1994). Experi-
mental data have suggested that these
T cells’ binding of HA via CD44 impacts
their migration to inflamed tissues that
are rich in HA by facilitating rolling interac-
tions of blood-borne effector T cells with
the postcapillary endothelium, which
allows for subsequent extravasation (De-
grendele et al., 1997). Such a model of
CD44 as an adhesion receptor of effector
cells targeted for inflamed tissues is in
agreement with the observation that its
genetic deficiency confers only a mild
immunological phenotype in healthy
mice (Schmits et al., 1997) but causes
immune dysfunction in several models of
infectious and inflammatory disease
(Pure´ and Cuff, 2001). However, many
other molecular functions of CD44 have
been described, such as signal transduc-
tion, coreceptor function, organization of
membrane proteins, or binding of matrix
metalloproteases for proteolytic activa-
tion of cytokines and pericellular ECM
degradation. Indeed, a more complexImmunity 29, Drole of CD44 in T cell function has already
been heralded, for example, by the finding
that it indirectly supports the role of
another T cell adhesion receptor, the
a4b1 integrin, through the formation of
a bimolecular complex via its cytoplasmic
domain (Nandi et al., 2004). Now Mrass
et al. (2008), by demonstrating that
CD44 also allows effector T cells to stabi-
lize polarity independent of its extracel-
lular domain, and at the same time high-
lighting its optimizing function in the
T cell-mediated elimination of tumors,
open up another exciting facet of CD44.
Mrass et al. (2008) focus on a mouse
model in which the adoptive transfer of
in vitro-primed, ovalbumin-specific cyto-
toxic T lymphocytes (CTLs) facilitates the
near-complete rejection of ovalbumin-
expressing tumors. CTLs genetically defi-
cient in CD44 initially reject these tumors
at the same pace as wild-type CTLs, but
they leave behind larger residual tumors
and allow for accelerated local recur-
rence. Upon careful comparative charac-
terization of CTLs lacking CD44, no
defects with respect to activation and
effector differentiation could be identified.ecember 19, 2008 ª2008 Elsevier Inc. 843
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into tumor-bearing recipients, the CD44-
sufficient cells had lost their transient
binding capacity for HA, and no HA
binding was detected on cells infiltrating
tumors after adoptive transfer. This
argues against a role for CD44-HA inter-
actions in the recruitment of CTLs into
tumors in this model. Accordingly, the
absolute number of CD44-deficient CTLs
in tumors 3 days after transfer, which is
the net result of influx, proliferation,
survival, and efflux, was unchanged
compared to that of their wild-type coun-
terparts.
The authors then went on to observe by
multiphoton microscopy the dynamic
behavior of CTLs in excised tumor tissue,
in which it is likely that many features of
the in vivo environment, such as the
microanatomic compartmentalization of
relevant substrates for cellular migration,
are preserved. Through diligent analysis
of their motility phenotype, the authors
demonstrate that CD44-deficient CTLs
are severely impaired in sustaining
a stable polarized shape, identified by
the formation of a mature uropod, and
can consequently only intermittently
migrate with the same directional persis-
tence and speed as their wild-type coun-
terparts (Figure 1). This defect results in
less efficient scanning of the tissue and
fewer contacts with individual tumor cells,
whereas upon successful engagement,
the dynamics and duration of these
contacts are unaltered.
In order to more precisely identify the
molecular defect underlying this pheno-
type, Mrass et al. (2008) genetically com-
plemented Cd44/ CTLs with various
recombinant DNA constructs coding for
CD44 proteins that lacked either the
extracellular domain, the intracellular
domain, or merely the nine amino acid-
long, positively charged domain needed
for the anchoring of CD44 to the actin
cytoskeleton via ezrin, radixin, moesin
(ERM) proteins. Surprisingly, it turned
out that the extracellular domain is
dispensable, whereas the ERM-binding
domain of the cytoplasmic tail is critical
for reconstituting the wild-type migratory
phenotype in artificial collagen matrixes.
This is because the CD44 ERM domain
is required for the proper recruitment of
CD44 to the uropod in polarized T cells,
which also allows for accumulation of
phosphorylated ERM proteins in the
same location. The authors conclude
from these findings that CD44 plays an
important role in T cell function by stabi-
lizing polarity in effector T cells, which
optimizes their scanning efficiency for
antigen-presenting target cells in periph-
eral tissues. Optimization of scanning
becomes relevant under conditions in
which target cells are scattered, such as
in tumors in advanced stages of immune-
mediated rejection.
These observations markedly extend
our understanding of the molecular deter-
minants of cell migration and raise several
interesting hypotheses and questions.
First, because CD44 is necessary for
polarity stabilization, what makes it
different from other uropod-localizing
molecules with ERM-binding motifs,
such as CD43 and ICAMs? Sequence
comparison between the CD44, CD43,
and ICAM-2 ERM domains revealed that
they share a strong positive charge but
differ substantially in terms of length and
amino acidic composition (Yonemura
et al., 1998). It is therefore likely that the
association of CD44 and ERM is modu-
lated through specific, but not-yet-char-
acterized, factors. In addition, although it
is evident from this study that CD44 lack-
ing its extracellular domain can stabilize
CTL polarity in vitro, it will be necessary
to explore whether it is also sufficient to
correct their migratory behavior in situ
and, more critically, their ability to reject
tumors in vivo. It remains possible that
here the extracellular domain contributes
by virtue of its manifold other functions
apart from binding HA. For instance, it
has been suggested that CD44 may also
serve as a costimulatory molecule in
T cell-receptor signaling by organizing
membrane proteins at the immunological
synapse (Foger et al., 2001). Although in
the current study CD44-deficient CTLs
were not impaired in their ability to lyse
tumor cells in vitro, this possibility was
tested with a high-affinity T cell receptor
recognizing an abundantly expressed
model antigen. Possibly, an optimizing
function of CD44 in this context could
become relevant under conditions of
suboptimal antigen-receptor signaling.
Another puzzling finding of this study is
that the motility of naive T cells in lymph
nodes is just fine in the absence of
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Figure 1. Cytoskeletal Anchorage of the Plasma Membrane Is a Critical Function of CD44 in
Effector T Cells
Without CD44, CTLs can still polarize. However, in absence of the CD44 ERM-binding motif, this polarity is
not stabilized, and the equilibrium between unstable and stable polarity states is shifted. As a conse-
quence, CD44-deficient CTLs only intermittently migrate with directional persistence and high speed,
which impairs their execution of effector functions by lowering the efficiency at which they scan the tissue
environment.
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action of CD44 with the extracellular envi-
ronment does not play a role in effector
T cell migration, it appears that during
effector differentiation, T cells develop
a dependency on CD44 to polarize. This
conclusion could be tested by investi-
gating the migration of effector T cells in
lymph nodes and examining whether the
tissue environment contributes to the
differential behavior of naive and effector
cells.
Beyond providing new insights into the
biology of CD44, this study also makes
an important contribution by highlighting
the relevance of events that take place in
peripheral tissues subsequent to recruit-
ment from the blood in determining theElite Suppression
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Rare HIV-1-infected individuals are
of Immunity, Migueles et al. (2008)
suppress viral replication by granzy
HIV-1 normally replicates vigorously in
untreated patients leading to global
immune activation, progressive CD4+
T cell depletion, and eventually frank
AIDS. This progressive course is not
seen in a select group of untreated
patients who suppress viral replication to
levels below the limit of detection of
commercial assays. These individuals,
who represent less than 0.5% of all HIV-
1-infected patients, have been called elite
controllers, elite suppressors, or HIV
controllers (Deeks and Walker, 2007). In
this issue of Immunity, Migueles et al.
(2008) refer to them simply as long-term
nonprogressors, but this term has tradi-
tionally been used to describe patients
who maintain relatively high CD4+ counts
for prolonged periods of time regardless
of the level of viral replication. The termoutcome of T cell responses. It is conceiv-
able that apart from the ability to migrate
properly, T cells need to execute many
other cellular functions that are subjected
to extrinsic regulation in order to carry out
their tasks.
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used in this preview. Understanding the
mechanisms responsible for the remark-
able control of viral replication in these
patients will obviously have major implica-
tions for the design of effective HIV-1
vaccines.
In a recent study, replication-compe-
tent HIV-1 was isolated from some HCs,
and detailed genotypic and phenotypic
analyses strongly suggested that these
isolates were fully virulent (Blankson
et al., 2007). Furthermore, a case of trans-
mission of HIV-1 from a patient who
developed AIDS to a subject who has
been an HC for 10 years has recently
been reported (Bailey et al., 2008). This
provides strong evidence that unique
host factors, and not infection with atten-
uated HIV-1 isolates, can explain the elite
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s from these individuals effectively
.
control of HIV-1 replication in at least
some of these individuals. The search is
on to determine exactly what these
protective host factors are. The most
consistent finding in studies of HCs is
that certain class I HLA alleles such as
HLA-B*57 and HLA-B*27 are overrepre-
sented in HCs compared to both the
general population and cohorts of HIV-
1-infected patients with progressive
disease (Deeks and Walker, 2007).
Furthermore, whole-genome association
scan analysis of HIV-1-infected individ-
uals has shown that the factors most
strongly associated with protection
against disease are either HLA alleles
(Fellay et al., 2007; Catano et al., 2008)
or a single-nucleotide polymorphism that
is in linkage disequilibrium with HLA-
B*5701 (Fellay et al., 2007). Taken
ecember 19, 2008 ª2008 Elsevier Inc. 845
